

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being transmitted to the Commissioner for Patents, Alexandria, VA, via the Office electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4), on the date below:

January 4, 2008

Date



Sharon V. Hart

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Thorpe and Ran

Serial No.: 09/998,833

Filed: November 30, 2001

For: COMBINED CANCER TREATMENT  
METHODS USING ANTIBODIES TO  
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Fetterolf

Atty. Dkt. No.: 4001.002299

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the documents listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. The required copies are enclosed, although copies of U.S. patents are no longer required under 37 C.F.R. § 1.98(a)(2)(ii).

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

An Official Action reflecting examination on the merits has been received in the present application. However, this Supplemental Information Disclosure Statement is being filed prior to the mailing of a final Official Action, Notice of Allowance or an Action that closes prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c).

The present Supplemental Information Disclosure Statement is being filed as a precaution in order to make of record documents cited in other applications of the present inventors concerning antibodies, immunoconjugates and therapeutic binding ligands that bind to aminophospholipids and their use in targeting tumor blood vessels.

Should a fee as set forth in 37 C.F.R. § 1.17(p) be deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement, such a fee should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.002299. Should any other fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the present materials, any such fees should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.002299.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.  
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

5353 W. Alabama, Suite 306  
Houston, Texas, 77056  
(713) 439-0108

Date: January 4, 2008